Impact News +++ Palantir stock plummets 20% from highs in longest losing streak since April 2024 (CNBC) +++ PALANTIR Aktie +3,58%

SCINAI Aktie

>SCINAI Aktienkurs

1.31 EUR -0.8% (Tradegate)

Ask: 1.31 EUR / 1600 Stück

Bid: 1.25 EUR / 1700 Stück

Tagesumsatz: 350 Stück

Realtime Kurs von 8 bis 22 Uhr!

SCINAI Aktie über LYNX handeln

Intraday

1 Jahr

>SCINAI Performance

1 Woche: +5,7%

1 Monat: -29,0%

3 Monate: -48,2%

6 Monate: -59,6%

1 Jahr: 0%

laufendes Jahr: -59,9%

>SCINAI Aktie

Name:

SCINAI IMMUNOTHERAPEUTICS ADR

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US09073Q3039 / A40DEH

Symbol/ Ticker:

2F5 (Frankfurt) / SCNI (NASDAQ)

Kürzel:

FRA:2F5, ETR:2F5, 2F5:GR, NASDAQ:SCNI

Index:

Webseite:

https://www.scinai.com/

Profil:

Scinai Immunotherapeutics Ltd is a biotechnology c..
>Volltext..

Marktkapitalisierung:

1.16 Mio. EUR

Unternehmenswert:

0.29 Mio. EUR

Umsatz:

1.06 Mio. EUR

EBITDA:

Nettogewinn:

3.75 Mio. EUR

Gewinn je Aktie:

5.03 EUR

Schulden:

Liquide Mittel:

0.87 Mio. EUR

Operativer Cashflow:

Bargeldquote:

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

SCINAI

Letzte Datenerhebung:

20.08.25

>SCINAI Kennzahlen

Aktien/ Unternehmen:

Aktien: 0.85 Mio. St.

Frei handelbar: 97.75%

Leerverk. Aktien: 32.28%

Rückkaufquote: -

Mitarbeiter: 31

Umsatz/Mitarb.: 0.02 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: -

Bewertung:

KGV: 0.27

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: 352.31%

Operative Marge: -628.63%

Managementeffizenz:

Gesamtkaprendite: -

Eigenkaprendite: -

>SCINAI Peer Group

Es sind 601 Aktien bekannt.

>SCINAI Chart & Kurs - NASDAQ

>SCINAI News

29.07.25 - 13:18	Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN (PR Newswire)
	New data builds on award-winning research and confirms efficacy and safety of PC111 across in-vitro, ex-vivo, and in-vivo humanized models JERUSALEM, July 29, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and......

26.06.25 - 13:39	Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" (PR Newswire)
	Dr. Roberta Lotti honoured for a pioneering work on PC111, reinforcing Scinai's strategic option agreement to acquire the Italian biotech company Pincell srl. JERUSALEM, June 26, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing......

05.06.25 - 15:03	Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. (PR Newswire)
	The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing Scinai to advance toward finalizing the transaction, subject to customary remaining conditions. JERUSALEM, June 5, 2025......

30.05.25 - 16:00	Scinai Immunotherapeutics reports Q1 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.05.25 - 13:01	Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn (PR Newswire)
	JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases......

07.05.25 - 22:03	Scinai Announces Annual Financial Results for 2024 (PR Newswire)
	JERUSALEM, May 7, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and......

01.05.25 - 13:00	Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases (PR Newswire)
	The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). JERUSALEM, Israel, May 1, 2025 /PRNewswire/ -- Scinai......

27.03.25 - 14:30	Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions (PR Newswire)
	Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) PC111 has already received an Orphan Drug......

17.03.25 - 12:01	Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025 (PR Newswire)
	JERUSALEM, March 17, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, today announced that it will be......

05.03.25 - 13:54	Scinai Immunotherapeutics announces $10M standby equity purchase agreement (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.03.25 - 13:33	SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT (PR Newswire)
	JERUSALEM, March 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business......

06.01.25 - 13:33	Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences (PR Newswire)
	JERUSALEM, Jan. 6, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced......

05.12.24 - 14:27	Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics′ Scientific Advisory Board (PR Newswire)
	JERUSALEM, Dec. 5, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices......

27.11.24 - 14:02	Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics′ Scientific Advisory Board (PR Newswire)
	JERUSALEM, Nov. 27, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business......

22.11.24 - 13:16	Scinai Publishes Financial Results and Provides Business Update; Shareholders′ Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million (PR Newswire)
	JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Am Anfang war die Kraft. - Paula Modersohn-Becker

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram